{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:16:34Z","timestamp":1774444594962,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008568","name":"Norske Kvinners Sanitetsforening","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007326","name":"Diakonhjemmet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Juvenile idiopathic arthritis (JIA) used to be a joint-destroying disease, but thanks to modern treatment strategies and medications, many patients with JIA today reach inactive disease. However, once disease remission is achieved, there is a lack of knowledge and recommendations regarding maintenance therapy. Drug-free remission is the ultimate goal in JIA, but withdrawal of medications increases the risk of disease flare. Clinical approaches vary widely, underscoring a need for knowledge about maintenance treatment strategies that allow for safe tapering and withdrawal of medications in JIA patients in sustained remission. The MOVE-JIA study is a randomized, controlled trial with the primary objective to compare the effect of two different treatment withdrawal strategies, to a stable dose of methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi), based on the risk of flares in children and adolescents with JIA with sustained inactive disease. A key secondary objective is the proportion of children with disease flare compared between the two withdrawal groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this investigator-initiated multicenter, randomized, 3-grouped, parallel, open-label, noninferiority trial, treating physicians at seven Norwegian pediatric rheumatology hospital centers will include 150 patients with JIA. Key eligibility criteria are as follows: Fulfilment of the International League of Associations for Rheumatology (ILAR) classification criteria for non-systemic JIA, inactive disease for\u2009\u2265\u200912\u00a0months documented at a minimum of 2 consecutive visits, and no active uveitis for\u2009\u2265\u200924\u00a0months under treatment with stable doses of MTX and TNFi.<\/jats:p>\n                    <jats:p>They will be randomized in a 1:1:1 ratio to (A) stable treatment, (B) methotrexate withdrawal, or (C) TNFi withdrawal. Randomization will be stratified for JIA subtype and study center. For patients in group B and C who are still in remission after 12\u00a0months, a new randomization will be performed for complete medication withdrawal for the next 12\u00a0months. After 24\u00a0months, medication adjustments will be done with shared decision-making. The primary endpoint is the rate of disease flare compared between the drug withdrawal groups and the stable treatment group between baseline and 12\u00a0months follow-up. The key secondary endpoint is the proportion with disease flare compared between the two withdrawal groups. Incidence and severity of adverse events will be monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results from the MOVE-JIA trial will present an evidence-based treatment strategy for JIA patients with inactive disease. The trial will also give us knowledge about regaining disease remission after flares and possibilities of drug-free remission. All outcomes from the trial will provide a scientific basis for optimized JIA care and result in new treatment recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EU CT 2024\u2013512017\u201312\u201300. Registered on October 24th, 2024; ClinicalTrials.gov NCT06653634. Registered on October 24th, 2024.<\/jats:p>\n                    <jats:p>URL: Study Details | NCT06653634 | Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE\u2013JIA Trial | ClinicalTrials.gov.<\/jats:p>\n                    <jats:p>Date of first recruitment: October 24th, 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09539-0","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:45:45Z","timestamp":1771310745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Moving towards optimized treatment for children and adolescents with juvenile idiopathic arthritis in sustained remission randomized to continue stable treatment, methotrexate withdrawal or tumor necrosis factor inhibitor withdrawal: study protocol for the Norwegian multi-center MOVE-JIA trial"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-2322","authenticated-orcid":false,"given":"Siri Opsahl","family":"Hetlevik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibke","family":"Lilleby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiju","family":"Pesonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Nordal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marite","family":"Rygg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathrine","family":"Austad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Karolina","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bilstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege Kilander","family":"H\u00f8iberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina Krafft","family":"Sande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Flat\u00f8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"Lillegraven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8yvind","family":"Molberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernille","family":"B\u00f8yesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Birgitte","family":"Aga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"9539_CR1","first-page":"386","volume":"30","author":"B Flat\u00f8","year":"2003","unstructured":"Flat\u00f8 B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol. 2003;30:386\u201393.","journal-title":"J Rheumatol"},{"key":"9539_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/BOR.0000000000000727","volume":"32","author":"IR Klein-Wieringa","year":"2020","unstructured":"Klein-Wieringa IR, Brinkman DMC, Ten Cate R, Hissink Muller PCE. Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible? Curr Opin Rheumatol. 2020;32:403\u201313.","journal-title":"Curr Opin Rheumatol"},{"key":"9539_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/ard-2022-222553","volume":"82","author":"LR Wedderburn","year":"2022","unstructured":"Wedderburn LR, Ramanan AV, Croft AP, Hyrich KL, Dick A. Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis. Ann Rheum Dis. 2022;82:449\u201356.","journal-title":"Ann Rheum Dis"},{"key":"9539_CR4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","volume":"75","author":"J Guzman","year":"2016","unstructured":"Guzman J, Oen K, Huber AM, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis. 2016;75:1092\u20138.","journal-title":"Ann Rheum Dis"},{"key":"9539_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/art.42240","volume":"74","author":"MH Chang","year":"2022","unstructured":"Chang MH, Bocharnikov AV, Case SM, et al. Joint-specific memory and sustained risk for new joint accumulation in autoimmune arthritis. Arthritis Rheumatol. 2022;74:1851\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"9539_CR6","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266\u201373.","journal-title":"JAMA"},{"key":"9539_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","volume":"78","author":"P Hissink Muller","year":"2019","unstructured":"Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78:51\u20139.","journal-title":"Ann Rheum Dis"},{"key":"9539_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3899\/jrheum.170794","volume":"45","author":"A Aquilani","year":"2018","unstructured":"Aquilani A, Marafon DP, Marasco E, et al. Predictors of flare following Etanercept withdrawal in patients with rheumatoid factor-negative juvenile idiopathic arthritis who reached remission while taking medication. J Rheumatol. 2018;45:956\u201361.","journal-title":"J Rheumatol"},{"key":"9539_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res. 2019;71:717\u201334.","journal-title":"Arthritis Care Res"},{"key":"9539_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/annrheumdis-2016-210511","volume":"76","author":"SJW Shoop-Worrall","year":"2017","unstructured":"Shoop-Worrall SJW, Verstappen SMM, Baildam E, et al. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. Ann Rheum Dis. 2017;76:1381\u20138.","journal-title":"Ann Rheum Dis"},{"key":"9539_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3899\/jrheum.161078","volume":"44","author":"DB Horton","year":"2017","unstructured":"Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the Childhood Arthritis and Rheumatology Research Alliance. J Rheumatol. 2017;44:352\u201360.","journal-title":"J Rheumatol"},{"key":"9539_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0508-1","volume":"17","author":"W Gidman","year":"2015","unstructured":"Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17:31.","journal-title":"Curr Rheumatol Rep"},{"key":"9539_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00495-4","volume":"19","author":"K S\u00f8rensen","year":"2021","unstructured":"S\u00f8rensen K, Skirbekk H, Kvarstein G, W\u00f8ien H. I don\u2019t want to think about it: a qualitative study of children (6-18\u2009years) with rheumatic diseases and parents\u2019 experiences with regular needle injections at home. Pediatr Rheumatol Online J. 2021;19:8.","journal-title":"Pediatr Rheumatol Online J"},{"key":"9539_CR14","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/rheumatology\/kez577","volume":"59","author":"A Klein","year":"2020","unstructured":"Klein A, Klotsche J, H\u00fcgle B, et al. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology (Oxford). 2020;59:2287\u201398.","journal-title":"Rheumatology (Oxford)"},{"key":"9539_CR15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Care Res. 2009;61:658\u201366.","journal-title":"Arthritis Care Res"},{"key":"9539_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202\u20139.","journal-title":"Arthritis Rheum"},{"key":"9539_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-016-0085-5","volume":"14","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Giancane G, Schiappapietra B, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol. 2016;14:23.","journal-title":"Pediatr Rheumatol"},{"key":"9539_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011;63:929\u201336.","journal-title":"Arthritis Care Res"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09539-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09539-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:31:50Z","timestamp":1774434710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09539-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9539"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09539-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Norwegian Ethics Committee for Clinical trials on Medicinal Products and Medical Devices (REK KULMU), Regional Committees for Medical and Health Research Ethics South Norway (REK s\u00f8r-\u00f8st) on the 28th of August 2024 (Clinical Trial Application EU CT 2024\u2013512017\u201312\u201300). The study has approval of data handling and protection of data safety at all participating sites. All participants are given age-appropriate oral and written information about the study. The legal guardians are provided with oral and written information, and informed consent is signed before enrollment in the study. The MOVE-JIA study will be conducted according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"229"}}